Antithrombotic therapy and survival in patients with malignant disease

British Journal of Cancer

Volumn 102, Issue , 2010, Pages S24-S29

  Kakkar, A K ^a   Macbeth, F ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

Antithrombotic therapy; Cancer survival; Thrombosis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ANTICOAGULANT THERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL PRACTICE; HUMAN; HYPERCOAGULABILITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR GROWTH; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 77950793588     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605602     Document Type: Article

References (27)

1. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266–1271
2. Carney DH, Mann R, Redin WR, Pernia SD, Berry D, Heggers JP, Hayward PG, Robson MC, Christie J, Annable C (1992) Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 89: 1469–1477
3. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7: 993–1002
4. ClinicalTrials.gov. Overall survival of inoperable gastric/gastrooesophageal cancer subjects on treating with LMWH + chemotherapy (CT) versus standard CT (GASTRANOX). http://clinicaltrials.gov/ct2/show/NCT007183540. Accessed 22 September 2009
5. Contrino J, Hair G, Kreutzer DL, Rickles FR (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2: 209–215
6. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Lowmolecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800–809
7. Green D, Hull RD, Brant R, Pineo GF (1992) Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339: 1476
8. Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME (1997) Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol 273: C239–C245
9. Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbut S, Williamson RC (1999) Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 86: 890–894
10. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC (1995) Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82: 1101–1104
11. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944–1948
12. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130–2135
13. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA (2007) The effect of lowmolecular- weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5: 729–737
14. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E, for ‘Petites Cellules’ Group (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 4: 38–45
15. Maurer LH, Herndon II JE, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 15: 3378–3387
16. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W (1998) A role for tissue factor in cell adhesion and migration mediated by interaction with actinbinding protein 280. J Cell Biol 140: 1241–1253
17. Petralia GA, Lemoine NR, Kakkar AK (2005) Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2: 356–363
18. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J (2003) Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9: 5339–5345
19. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 342: 1953–1958
20. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81: 758–767
21. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS (1996) Low-molecularweight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100: 269–277
22. Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR (2007) Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 8: 395–402
23. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP (2004) Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23: 410–417
24. Wales Cancer Trials Unit. FRAGMATIC: a randomised phase III clinical trial investigating the effect of FRAGMin Added to standard Therapy In patients with lung Cancer. http://www.wctu.org.uk/fragh.htm. Accessed 22 September 2009
25. Wang X, Wang M, Amarzguioui M, Liu F, Fodstad O, Prydz H (2004) Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 112: 994–1002
26. Zacharski LR, Henderson WG, Rickles RR, Forman WB, Cornell Jr CJ, Forcier AJ, Edwards RL, Headley E, Kim S-H, O’Donnell JF, O’Dell R, Tornyos K, Kwaan HC (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53: 2046–2052
27. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94: 1320–1327